# Case Report: long complete metabolic response assessed by LAFOV FDG-PET/CT to FOLFIRINOX in first-line treatment of metastatic low-differentiated pancreatic carcinoma

## TL;DR

A 56-year-old patient with advanced pancreatic cancer showed a long-lasting complete metabolic response to FOLFIRINOX chemotherapy, as detected by FDG-PET/CT.

## Contribution

This case report presents a rare long-term complete metabolic response to FOLFIRINOX in metastatic pancreatic cancer using FDG-PET/CT.

## Key findings

- The patient showed a sustained metabolic complete response over 23 months.
- FDG-PET/CT was used to assess the treatment response in metastatic pancreatic cancer.
- This case suggests the potential of FDG-PET/CT in evaluating systemic cancer therapies.

## Abstract

FOLFIRINOX chemotherapy is recommended as first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC). While its efficacy has been well documented in clinical trials, the responses observed have been predominantly partial. To date, only rare cases of complete response (CR) assessed by CT scan have been reported in the literature.

We present a case of sustained metabolic CR over 23 months assessed by LAFOV FDG-PET/CT in a 56-year-old male patient with poorly differentiated mPDAC treated with FOLFIRINOX.

This case highlights the emerging role of latest generation of digital FDG-PET/CT in assessing the therapeutic efficacy of systemic treatments for solid cancers.